Currently, several active clinical trials are testing anti-NKG2A blockade in patients with cancer (ClinicalTrials.gov NCT02671435, NCT02643550, NCT03822351, NCT03794544), with one that has published results reporting a 27.5% overall response rate when administered in combination with cetuximab to patients with squamous cell carcinoma of the head and neck (33). The gene discussed is KLRC1; the disease is cancer.